According to the WHO International Agency for Research on Cancer (IARC), 13 genotypes of HPV, including HPV16 and HPV18, are classified as high-risk. Additionally, five other genotypes, such as HPV53 and HPV66, are categorized as medium-risk. The HPV test kit developed by Sansure targets these crucial genotypes, facilitating cervical cancer screening and risk assessment.
Key Features of the S3057E HPV 13+2 Diagnostic Kit
The S3057E HPV test kit employs PCR-Fluorescence Probing technology, allowing for the detection of 15 target genotypes. This kit is particularly effective for females aged 30 and above, especially those with positive HPV results for high-risk types like HPV16 and HPV18. The diagnostic kit also supports subtype identification, enhancing the accuracy of cervical cancer screening.
Risk Evaluation and Immediate Action
The guidelines indicate that females over 30 with positive HPV detection should undergo further examinations, such as vaginoscopy, particularly if infected with HPV16 or HPV18. The HPV test kit by Sansure provides essential data for healthcare professionals to make informed decisions regarding patient management.
Global Reach and Impact
By integrating advanced technology into their HPV test kit, Sansure is contributing significantly to global health initiatives aimed at reducing cervical cancer rates. The ability to accurately identify high-risk and medium-risk HPV types allows healthcare providers to implement timely interventions, ultimately improving patient outcomes.
Conclusion
In conclusion, the HPV test kit is a vital tool in the fight against cervical cancer. The S3057E HPV 13+2–Human Papillomavirus DNA Diagnostic Kit by Sansure offers a reliable and efficient solution for HPV screening and risk evaluation. By focusing on high-risk genotypes, this kit empowers healthcare providers to take proactive measures in patient care. As awareness and testing for HPV continue to grow, Sansure remains committed to advancing diagnostic solutions that enhance public health and safety.